Osteoporosis & Bone Health and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 7 records for MSC in Osteoporosis & Bone Health: 0 recruiting now, 0 labelled Phase 3 or 4, across 6 countries. Snapshot 2026-08-29.
Why this is studied in Osteoporosis & Bone Health
Osteoporosis is loss of bone mineral density and microarchitecture, and it already has drugs with fracture-reduction evidence. Cell approaches target osteoblast function or marrow niche support, so any new entrant has to be judged against established therapy rather than against nothing.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (osteoporosis x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 7 |
| Interventional studies in the sample | 7 |
| Recruiting right now | 0 |
| Completed | 2 |
| Terminated, withdrawn or suspended | 3 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 6 |
| Median planned enrolment | 9 participants |
| Largest single planned enrolment | 58 participants |
| First / most recent start year | 2012 — 2025 |
How mature is this evidence?
Registration activity is thin and early: 7 records in total, none at confirmatory phase, 0 recruiting.
2 records are marked completed and 3 ended early (terminated, withdrawn or suspended): 43% of registrations did not run to plan.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 5 | 62% |
| Phase 2 | 3 | 38% |
Median planned enrolment is 9 participants (largest single study: 58). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
6 countries host at least one site. United States is the largest single contributor at roughly 29% of country mentions in this sample.
| Country | Studies with a site there |
|---|---|
| United States | 2 |
| Antigua and Barbuda | 1 |
| Switzerland | 1 |
| Spain | 1 |
| China | 1 |
| Indonesia | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Among the top lead sponsors, 2 are universities or hospitals and 4 are companies, making this a commercial area.
- The Foundation for Orthopaedics and Regenerative Medicine — 1 record
- University Hospital, Basel, Switzerland — 1 record
- Red de Terapia Celular — 1 record
- HELP Therapeutics Co., Ltd. — 1 record
- Nancy E. Lane, MD — 1 record
- Ahmad Jabir Rahyussalim — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT06949137 — Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture | Phase 1 | Active Not Recruiting | 9 | HELP Therapeutics Co., Ltd. | 2025-06-20 |
| NCT05284604 — Mesenchymal Stem Cells for Age-Related Frailty | Phase 1, Phase 2 | Withdrawn | n/a | VA Office of Research and Development | 2023-01-31 |
| NCT04501354 — Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients | Phase 2 | Unknown | 5 | Ahmad Jabir Rahyussalim | 2020-08 |
| NCT01532076 — Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts | Phase 2 | Terminated | 8 | University Hospital, Basel, Switzerland | 2012-06 |
| NCT05152381 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis | Phase 1 | Withdrawn | n/a | The Foundation for Orthopaedics and Regenerative Medicine | 2022-12-08 |
| NCT03197623 — Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids | Phase 1 | Completed | 58 | Nancy E. Lane, MD | 2016-10-14 |
| NCT02566655 — Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis | Phase 1 | Completed | 10 | Red de Terapia Celular | 2015-09 |
What this page does and does not tell you
These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Osteoporosis & Bone Health are recruiting right now?
0 of 7 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Osteoporosis & Bone Health?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 7 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Osteoporosis & Bone Health?
0 of 7 records carry a Phase 3 or Phase 4 label and 2 are marked completed. Registrations run from 2012 to 2025.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.